Abstract 207P
Background
Diabetes mellitus is considered as a potential risk factor for breast cancer, yet the relationship between diabetic background retinopathy (DBR) and breast cancer remains uncertain. This study leverages mendelian randomization (MR) to explore the genetic link between diabetic background retinopathy (DBR) and estrogen receptor-positive (ER+) breast cancer, highlighting the connection with diabetes-related conditions.
Methods
We acquired summary data from a genome-wide association study (GWAS) concerning DBR in the European population, with a focus on their relationship with ER+ breast cancer. We performed two-sample MR analysis with multiple approaches to evaluate the potential causal associations between DBR and ER+ breast cancer. Pleiotropy and Cochran's Q tests were utilized to determine horizontal pleiotropy and heterogeneity.
Results
Of the 205,044 participants (2,026 DBR cases) from FinnGenn, we identified 8 single nucleotide polymorphisms (SNPs) associated with the risk of ER+ breast cancer (69,501 ER+ breast cancer cases from iCOGS). The MR analysis showed a suggestive association between DBR susceptibility and ER+ breast cancer (weight median odds ratio [OR]: 0.971, 95% confidence interval [CI]: 0.955-0.987, P = 0.0006; simple mode OR: 0.964, P = 0.043; weight mode OR: 0.971, P = 0.015). The effect size estimate (β) for weight median model was -0.0294, indicating a 2.94% decrease in the odds of ER+ breast cancer per unit increase in genetically predicted DBR. Sensitivity analyses are consistent with the results, manifesting that our findings were convincing and robust.
Conclusions
These finding suggests that a potential inverse relationship between DBR and the risk of ER+ breast cancer. These findings could significantly impact screening and prevention strategies for diabetic populations, emphasizing the need for further research into this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
202P - eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS G12C NSCLC to KRAS inhibitors
Presenter: Andrew Truong
Session: Poster session 09
203P - An innovative evidence-based laboratory medicine (EBLM) test to help doctors in multi-cancer early detection (MCED)
Presenter: Jose D Santotoribio
Session: Poster session 09
204P - Assessing biomarker testing awareness among patients and caregivers in NSCLC through an interdisciplinary global survey
Presenter: Rodrigo Paredes
Session: Poster session 09
205P - Detection and diagnosis of lung cancer by electronic nose analysis of exhaled breath: A multi-center prospective observational study
Presenter: Alessandra Buma
Session: Poster session 09
206P - Unveiling the link: How metabolic syndrome drives endometrial cancer progression
Presenter: Lirong Zhai
Session: Poster session 09
Resources:
Abstract
208P - Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?
Presenter: Daniele Fanale
Session: Poster session 09
209P - A novel method for early evaluation of drug-specific predictive biomarker
Presenter: Gal Dinstag
Session: Poster session 09
210P - Therapeutic implications of phosphoproteomics in molecular cancer diagnostics
Presenter: Annika Schneider
Session: Poster session 09
211P - GynePDX: A new platform of preclinical models for endometrial and ovarian cancers
Presenter: Melek Denizli
Session: Poster session 09
212P - BRGSF-HIS mice as a predictive tool for safety assessment of biologics
Presenter: Kader Thiam
Session: Poster session 09